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Patients with pancreatic ductal adenocarcinoma (PDAC) are frequently complicated with metastatic
disease or locally advanced tumors, and consequently need chemotherapy. Gemcitabine is commonly
used for PDAC treatment, but with limited efﬁcacy. The capacity of gemcitabine to generate reactive
oxygen species (ROS) in human pancreatic cancer cells, prompted us to examine its effects on the
expression of pro-inﬂammatory cytokines and chemokines. We observed that gemcitabine enhanced
selectively the expression of CXCL8 in human pancreatic cancer cells through ROS generation and NF-kB
activation. In vitro blocking of CXCL8 failed to modulate gemcitabine-mediated inhibition of cell pro-
liferation in human pancreatic cancer cells. Gemcitabine also enhanced CXCL8 expression in pancreatic
cancer cells in xenografted tumor tissues. Moreover, anti-CXCL8 antibody treatment in vivo attenuated
tumor formation as well as intra-tumoral vascularity in nude mice, which were transplanted with
Miapaca-2 cells and treated with gemcitabine. Thus, gemcitabine-induced CXCL8 may counteract the
drug through inducing neovascularization.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a tumor within the
exocrine compartment of pancreatic gland [1]. About 80% PDAC
cases are diagnosed with metastatic disease or with locally invasive
tumors, and are subjected to chemotherapy. The rest of the patients
are eligible for curative resection, but frequently develop local
recurrence or distant metastasis after surgery. As a consequence,
they also need chemotherapy.
Gemcitabine, an analogue of cytosine arabinoside (Ara-C) [2], is
used as a standard drug for PDAC treatment, alone or in combina-
tion with other chemotherapeutics [1,3]. Gemcitabine is trans-
ported into cells across the cell membrane through multiple active
nucleoside transporters [4], and is phosphorylated bytion; ELISA, enzyme-linked
nocarcinoma; ROS, reactive
N. Mukaida).deoxycytidine kinase to produce gemcitabine monophosphate
(dFdCMP), which is further converted to active drug metabolites,
gemcitabine diphosphate (dFdCDP) and gemcitabine triphophage
(dFdCTP) [5]. dFdCTP directly inhibits DNA polymerase [6], cytidine
triphosphate synthetase [7] and deoxycytidylate deaminase [8],
and is incorporated into DNA, thereby terminating chain elongation
[9]. dFdCDP potently inhibits ribonucleotide reductase (RR),
thereby decreasing deoxynucleotide pools [10]. Despite its multiple
intracellular targets, the resistance to gemcitabine often ensues [1].
Evidence is accumulating to indicate that gemcitabine induced
reactive oxygen species (ROS) generation [11]. Moreover, the
resultant ROS activated a transcription factor NF-kB [11], which has
a crucial role in the activation of various pro-inﬂammatory genes,
including cytokine and chemokine genes [12]. Consistently, we
observed that gemcitabine induced ROS generation in a human
pancreatic cancer cell line, Miapaca-2. Hence, we evaluated the
effects of gemcitabine on chemokine and cytokine expression in
human pancreatic cancer cell lines. Indeed, gemcitabine induced
abundant expression of CXCL8 in human pancreatic cancer cells
in vivo as well as in vitro. Moreover, endogenously-produced CXCL8
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proliferation of pancreatic cancer cells. However, CXCL8 can coun-
teract the in vivo action of gemcitabine by promoting
neovascularization.
2. Materials and methods
2.1. Cell lines and reagents
Miapaca-2 and Panc-1 cells were obtained from ATCC and were
maintained in RPMI-1640 medium supplemented with 10% fetal
bovine serum. Mouse anti-human CXCL8 monoclonal and rabbit
anti-human CXCL8 polyclonal antibodies were prepared as
described previously [13]. The following antibodies were obtained
commercially: rabbit anti-NF-kB/p65 polyclonal antibodies (Cell
Signaling Technology, Beverly, MA); mouse IgG1 (SigmaeAldrich,
St. Louis, MO); rabbit immunoglobulin fraction (Dako, Glostrup,
Denmark). N-acetyl cysteine (NAC) and gemcitabine were obtained
from Sigma Aldrich.
2.2. Determination of intracellular ROS concentration by a ﬂow
cytometry
Intracellular ROS concentration was determined by using total
ROS/superoxide detection kit (Enzo Life Science, San Diego, CA)
according to the manufacturer's instructions. In brief, after
Miapaca-2 cells were pre-treated with or without NAC (30 mM) for
1 h, the cells were further incubated in the absence or the presence
of gemcitabine (10 mM) for 24 h. Then, the cells were collected and
incubated with ROS/superoxide detection solution for 10 min at
37 C. At least 50,000 stained cells were analyzed on a FACSCanto II
system (Becton Dickinson, Bedford, MA) by using 490 nm and
525 nm wave lengths as excitation and emission wave lengths,
respectively, for each determination.
2.3. In vitro cell proliferation
Cell suspensions (2  103 cells/100 ml) were added to a well of
96-multi-well plates and incubated at 37 C for 24 h. Then, the cells
were treated with the indicated concentrations of gemcitabine for
the indicated time intervals. The cell viability was determined by
using the cell counting kit-8 (Dojindo Co. Ltd., Kumamoto, Japan).
The ratios of cell numbers were determined by comparing the cell
numbers at day 0.
2.4. Assays of secreted CXCL8
Culture supernatants were collected from Miapaca-2 or Panc-1
cells at the indicated time intervals after gemcitabine treatment,
to determine CXCL8 contents by using enzyme-linked immuno-
sorbent assay (ELISA) for human CXCL8 (R&D Systems, Minneap-
olis, MN).
2.5. Transfection of CXCL8 siRNA
Miapaca-2 or Panc-1 cells were seeded at a density of
1  105 cells/well in 2 ml in a 6-well plate. After overnight incu-
bation, CXCL8 or control siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA) was transduced into Miapaca-2 and Panc-1 cells using a
JetPRIME DNA & siRNA transfection reagent (Polyplus Trans-
fections, Illkirch, France) and siRNA transfection reagent (Santa
Cruz Biotechnology), respectively. The cells were then incubated
with or without gemcitabine (10 mM) for 48 h and were subjected
to proliferation assay or total RNA extraction.2.6. RNA isolation for RT-PCR
Total RNA was isolated and was reverse transcribed to cDNA as
previously described [14]. The resultant cDNA was ampliﬁed to
detect human CXCR1 and CXCR2 mRNA by using the speciﬁc sets of
the primers, 5’-CCCCTGTATGCTAGAAACTGAGAC-3’ (CXCR1 for-
ward), 5’-CCAGCAGCCAAGACAAACAAAC-3’ (CXCR1 reverse), 5’-
CATGGGCAACAATACAGCAA-3’ (CXCR2 forward) and 5’-TGAGGAC-
GACAGCAAAGATG-3’ (CXCR2 reverse) with 30 cycles consisting of
94 C for 30 s, 55 C for 30 s and 68 C for 1 min, and with a ﬁnal
extension at 68 C for 5 min. Ampliﬁed DNA fragments were
resolved by electrophoresis on 2% agarose gels and visualized by
ethidium bromide staining under ultraviolet light trans-
illumination. GAPDH was used as a positive control. Quantitative
(q)RT-PCR for CXCL8 was performed using the sets of the primers,
5’-TGGCAGCCTTCCTGATTTCT-3’ (forward) and 5’-TTTCTGTGTTGGC
GCAGTGT-3’ (reverse) and mRNA amounts were normalized to the
amounts of GAPDH as relative expression values as described pre-
viously [14].
2.7. Luciferase assay
Miapaca-2 cells were cultured at a concentration of 1105 cells/
well in a 6-well plate for 24 h. Then, the cells were transfected with
the luciferase expression vectors containing various deleted or
mutated 5’-ﬂanking region of the CXCL8 promoter [15] (1.5 mg) and
SV40-renilla luciferase expression vector (37.5 ng) as a control by
using a JetPRIME DNA & siRNA transfection reagent. Cells were
incubated for additional 48 h with or without gemcitabine (10 mM).
Thereafter, the cells were harvested to determine luciferase activ-
ities with the use of the Dual Luciferase Reporter Assay System
(Promega, Madison, WI). Fireﬂy luciferase values were normalized
to Renilla luciferase activities.
2.8. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the ChIP assay kit (Upstate
Biotechnology, Lake Placid, NY). Miapaca-2 cells were cross-linked
with 1% formaldehyde for 10 min at 37 C and harvested in sodium
dodecyl sulfate lysis buffer. The resultant chromatinwas sheared to
generate fragments of about 500 bp by sonication. Then, each
aliquot of chromatin received anti-p65 (Cell Signaling Technology)
or control antibodies, and was incubated at 4 C overnight. The
mixtures received Protein A agarose (Life Technology, Carlsbad, CA)
andwere incubated for additional 1 h at 4 C. DNAwas recovered by
phenolechloroform extraction followed by ethanol precipitation.
The resultant DNA underwent PCR using the sets of the primers, 5’-
GGAACAAATAGGAAGTGTGATGAC-3’ (forward) and 5’-AGA-
GAACTTATGCACCCTCATCT-3’ (reverse), to amplify the 112 bp-long
fragment, which contains the NF-kB/p65 binding site in the hu-
man CXCL8 promoter, under the conditions consisting of an initial
denaturation at 94 C for 5 min followed by 28 cycles of 94 C for
30 s, 55 C for 30 s, and 68 C for 1 min, with a ﬁnal extension at
68 C for 5 min. The resultant PCR products were fractionated on
12% polyacrylamide gel and visualized by ethidium bromide
staining under ultraviolet light transillumination.
2.9. Animal experiments
Miapaca-2 cells were suspended in HBSS at a concentration of
3.5  107 cells/ml and 200 ml cell suspensions were injected sub-
cutaneously into the back of BALB/c nu/nu mice (SLC, Shizuoka,
Japan). After the tumor size reached 100mm3, gemcitabine (30mg/
kg body weight) was administered four times on day 1, 5, 8, and 12,
while anti-human CXCL8 monoclonal antibody or control antibody
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sizes were determined every 3e4 days and its volumes were
calculated as follows. Tumor volume (mm3) ¼ (the longest diam-
eter) (mm)  (the shortest diameter)2 (mm)/2. At the indicated
time points after the injection, tumors were removed for immu-
nohistochemical analysis using anti-human CXCL8, anti-mouse
CD31 (Abcam, Cambridge, UK), or anti-mouse Ly6G antibody (BD
Biosciences) as previously described [14]. All animal experiments
were performed in compliance with the Guidelines for the Care and
Use of Laboratory Animals of Kanazawa University.
2.10. Statistical analysis
Data was analyzed statistically using methods indicated in each
ﬁgure legend. p < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Gemcitabine-induced CXCL8 expression in pancreatic cancer
cells
Consistent with the previous report [11], gemcitabine induced
ROS generation in Miapaca-2 cells (Fig. 1A). Given the capacity of
ROS to activate NF-kB [16] with a crucial role in the expression of
pro-inﬂammatory cytokines and chemokines [12], we examined
the effects of gemcitabine on the expression of pro-inﬂammatory
cytokines and chemokines including interleukin (IL)-1, IL-6,
CXCL8/IL-8, CXCL1, CCL2/monocyte chemoattractant protein
(MCP)-1, CCL3/macrophage inﬂammatory protein (MIP)-1a, CCL4/Fig. 1. Gemcitabine-induced CXCL8 expression in human pancreatic cancer cell lines. A. Miap
1 h pretreatment with NAC. Then, intracellular ROS levels were determined. Representative
treated with the indicated concentrations of gemcitabine for 24 or 48 h. Supernatants were
while total RNA was extracted to determine CXCL8 mRNA levels by qRT-PCR (C). Mean and
p < 0.01 using one-way ANOVA followed by the Dunnett test, compared with untreated. D.
after 1 h pretreatment with NAC. Total RNA was extracted to conduct qRT-PCR to determine C
are shown here. **, p < 0.01 using Student's t-test.MIP-1b, CCL7/MCP-3, CCL11/eotaxin, and CX3CL1/fractalkine, in
Miapaca-2 by using Mutiplex immunoassay system. Gemcitabine
enhanced selectively IL-8/CXCL8 secretion among these molecules
in Miapaca-2 cells (data not shown). Consistent with these obser-
vations, gemcitabine enhanced CXCL8 protein (Fig. 1B) and mRNA
expression in a dose-dependent manner (Fig. 1C). Similar obser-
vations were obtained for another human pancreatic cancer cell
line, Panc-1 (data not shown). We next examined the effect of a
thiol-containing antioxidant, NAC, which is a precursor of reduced
glutathione, with a capacity to scavenge ROS by interacting with
OH$ and H2O2 [17]. NAC reduced gemcitabine-induced ROS gen-
eration (Fig. 1A) and CXCL8 mRNA expression (Fig. 1D). Thus,
gemcitabine induced CXCL8 expression in human pancreatic cancer
cells through ROS generation.3.2. Indispensable roles of NF-kB activation in gemcitabine-induced
CXCL8 expression
Gemcitabine enhanced luciferase activities when Miapaca-2
cells were transduced with the reporter gene under the control of
the 546, 272 or 133 bp CXCL8 promoter/enhancer region (Fig. 2A
and B). The mutation in NF-kB binding site abrogated the
gemcitabine-induced enhancement in luciferase activities, whereas
the mutation in either AP-1 or NF-IL-6 binding site had minimal
effects (Fig. 2C). Moreover, ChIP assay revealed that gemcitabine
induced the binding of a component of NF-kB, p65, to CXCL8 pro-
moter in Miapaca-2 cells (Fig. 2D). Thus, NF-kB activation is indis-
pensable to gemcitabine-induced CXCL8 expression.aca-2 cells were incubated in the absence or the presence of gemcitabine for 24 h with
results from 3 independent experiments are shown here. B and C. Miapaca-2 cells were
collected to determine CXCL8 contents by using a speciﬁc ELISA for human CXCL8 (B)
1 SE were calculated for 3 independent experiments and are shown. *, p < 0.05; **,
Miapaca-2 cells were incubated in the absence or the presence of gemcitabine for 48 h
XCL8 mRNA levels. Mean and 1 SE were calculated for 3 independent experiments and
Fig. 2. Crucial roles of NF-kB activation in gemcitabine-induced CXCL8 expression. A. Schematic structure of 50 promoter/enhancer region of human CXCL8 gene and luciferase
expression linked with deleted or mutated 50 promoter region of human CXCL8 gene. B and C. The cells were transiently transfected with CXCL8 promoter/enhancer-driven
luciferase expression vectors together with SV40-renilla luciferase expression vector. After the cells were treated with or without gemcitabine for 48 h, they were harvested to
determine their luciferase activities. Mean and 1 SE calculated for 3 independent experiments are shown. D. ChIP assay was conducted. Input indicates the results when total
nuclear lysates were used without any immunoprecipitation. Representative results from 3 independent experiments are shown.
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cellular proliferation
We could not detect expression of mRNA of speciﬁc receptors for
CXCL8, CXCR1 and CXCR2, in untreated or gemcitabine-treated
Miapaca-2 and Panc-1 cells (Fig. 3A). Consistently, ﬂow cyto-
metric analysis failed to detect CXCR1 and CXCR2 expression on
untreated or gemcitabine-treated Miapaca-2 and Panc-1 cells (data
not shown). CXCL8 siRNA efﬁciently inhibited gemcitabine-induced
CXCL8 expression (Fig. 3B), but failed to modulate gemcitabine-Fig. 3. Roles of CXCL8 in gemcitabine-induced inhibition of cell proliferation. A. Miapaca-2
concentrations of gemcitabine for the indicated time intervals. Cells were then harvested a
sentative results from 3 independent experiments are shown here. B and C. Miapaca-2 cells
CXCL8 mRNA expression was determined by using qRT-PCR (B). The transfected cells were
determined (C). Mean and 1 SE were calculated for 3 independent experiments and are shinduced reduction in cell proliferation in either cell line (Fig. 3C).
Thus, gemcitabine-induced CXCL8 expression had few effects on
cellular growth of human pancreatic cancer cells in an autocrine
manner.
3.4. Involvement of gemcitabine-induced CXCL8 expression in
in vivo tumor growth
We ﬁnally examined the effects of gemcitabine on CXCL8
expression in xenotransplanted tumor tissues. Gemcitabinecells (upper panels) and Panc-1 cells (lower panels) were treated with the indicated
nd subjected to RT-PCR analysis to detect CXCR1 or CXCR2 mRNA expression. Repre-
(left panel) or Panc-1 cells (right panel) were transfected with CXCL8 or control siRNA.
incubated with the indicated concentrations of gemcitabine for 48 h. Cell viability was
own here. *, p < 0.05; **, p < 0.01 using Student's t-test.
Fig. 4. Gemcitabine-induced CXCL8 expression in xenotransplanted tumor tissues. A. Miapaca-2 cells (7  106) were subcutaneously injected into nude mice. After tumor was
formed, gemcitabine (30 mg/kg) or PBS was administered intraperitoneally as described in Materials and method. Tumor tissues were obtained 7 or 14 days after the start of
gemcitabine treatment and were subjected to immunohistochemical analysis using anti-human CXCL8. Representative results from 3 independent animals are shown here with a
scale bar of 100 mm. B. Tumor volumes were determined every 3e4 days after the initiation of gemcitabine and/or anti-CXCL8 antibody treatment. Each group consists of at least 10
tumors. Mean and 1 SE were calculated for 3 independent experiments and are shown here. *, p < 0.05, using one-way ANOVA, followed by the TukeyeKramer test. C and D. At 14
days after the initiation of gemcitabine and/or anti-CXCL8 antibody treatment, tumors were removed and subjected to immunohistochemical analysis using anti-Ly6G (C) or anti-
CD31 antibodies (D). Ly6G-postive cell numbers (C) or CD31-positive areas (D) were determined. Mean and 1 SE were calculated for 3 individual samples and are shown. *, p < 0.05
using one-way ANOVA, followed by the TukeyeKramer test.
Y. Song et al. / Biochemical and Biophysical Research Communications 458 (2015) 341e346 345induced CXCL8 mRNA expression (data not shown) and CXCL8
protein expression in pancreatic cancer cells in xenografted tumor
tissues (Fig. 4A). We next administered anti-CXCL8 antibody in
combination with gemcitabine after xenografted Miapaca-2 cells
formed tumor in mice. Tumor growth rates were reduced by the
combined treatment of gemcitabine and anti-CXCL8 antibody but
not with that of either single agent (Fig. 4B). Anti-CXCL8 antibody
failed to reduce Ly6G-positive granulocytes (Fig. 4C) and F4/80-
positive macrophages (data not shown). On the contrary, the
treatment markedly reduced CD31-positive vascular areas (Fig. 4D).
Thus, gemcitabine enhanced tumor cell-derived CXCL8 expression,
which augmented intratumoral neovascularization, and eventually
promoted in vivo tumor growth.4. Discussion
CXC chemokines are divided into ELR-positive or ELR-negative
CXC chemokines on the basis of the 3 amino acid sequence con-
sisting of glutamic acid-leucine-arginine (the “ELR” motif) imme-
diately preceding the ﬁrst cysteine residue [18]. Most ELR-positive
CXC chemokines utilize selectively CXCR2, except for CXCL6 and
CXCL8 which utilize CXCR1 as well as CXCR2 [18e20]. CXCL8 is a
potent chemotactic factor for neutrophils and has a crucial role in
various types of neutrophil-mediated acute inﬂammation [21].
CXCR1 and CXCR2 are coordinately expressed by human neutro-
phils [22] and bind CXCL8 to induce a group of equipotent re-
sponses including chemotaxis and exocytosis [23]. However, they
couple to distinct G proteins [24] to differentially generate other
signals such as receptor internalization and phospholipase D acti-
vation [23] and these signals are required for full responsiveness of
human neutrophils to CXCL8. Because mice do not possess the
functional CXCR1 genes [25], human CXCL8 produced bygemcitabine-treated human cancer cells, could not fully induce
mouse neutrophil responses and as a consequence, anti-CXCL8
antibody failed to reduce neutrophil inﬁltration under these
conditions.
Tumor growth depends on the interaction with tumor micro-
environment consisting of non-leukocytic cells including endo-
thelial cells and ﬁbroblasts as well as leukocytes [26]. Tumor
microenvironment is inﬂuenced by various inﬂammatory mole-
cules. Gemcitabine induced a robust production of CXCL8 in
Miapaca-2 and Panc-1 cells. This chemokine can promote the
migration and proliferation of endothelial cells, after binding
mainly CXCR2 expressed by endothelial cells [27,28]. Moreover,
accumulating evidence indicates the crucial roles of CXCL8 in tumor
neovascularization in several animal tumor models, as evidenced
by reduced tumor angiogenesis by CXCL8 blockade [29,30]. Like-
wise, we observed that anti-CXCL8 antibody treatment reduced
intra-tumoral neovascularization as well as tumor sizes in mice
treated with gemcitabine. Thus, gemcitabine treatment may
counteract its anti-tumor effects by inducing a potent angiogenic
factor, CXCL8, and CXCL8 blockade may be effective to enhance the
efﬁcacy of gemcitabine.Conﬂict of interest
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